Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12567654 | 0.94 | MAOB (0.35) | ALDH1A1MAOBMAOACYP1A2CYP2C9 | |
| SCHEMBL12731130 | 0.93 | ALDH1A1 (0.35) | ALDH1A1MAOBMAOACYP1A2CYP2C9 | |
| SCHEMBL12154240 | 0.88 | ALDH1A1 (0.38) | ALDH1A1MAOBMAOACYP1A2CYP2C9 | |
| SCHEMBL5961815 | 0.84 | THRB (0.33) | MAOBTDP1L3MBTL1 | |
| SCHEMBL12154239 | 0.83 | MAOB (0.37) | MAOBMAOACYP1A2PPARDPARP14 | |
| SCHEMBL13289965 | 0.80 | POLB (0.45) | MAOBMAOAPARP14PARP10 | |
| SCHEMBL12567642 | 0.80 | THRB (0.34) | MAOBTDP1L3MBTL1 | |
| SCHEMBL12154248 | 0.79 | MAOB (0.39) | ALDH1A1MAOBMAOAPARP10 | |
| SCHEMBL13289955 | 0.78 | MAOB (0.35) | ALDH1A1MAOBMAOAPARP14PARP10 | |
| SCHEMBL12154246 | 0.78 | ESR1 (0.43) | MAOBMAOATDP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168734-B2 | Lateral alpha-substituted acrylate compound and polymer thereof | JNC CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | CHISSO CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | LEF1, AFF1, CNKSR1 | ALDH1A1 620/4885MAOB 3983/4885MAOA 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.